Liraglutide: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข3 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Store refrigerated at 2-8 degrees C (36-46 degrees F). Do not freeze. After first use, pen may be stored at room temperature (up to 30 degrees C / 86 degrees F) or refrigerated for up to 30 days. Protect from direct heat and sunlight. Keep pen cap on when not in use. Discard pen after 30 days even if medication remains.
Protocol Quick-Reference
Weight management (Saxenda) and type 2 diabetes (Victoza)
Dosing
Amount
0.6 mg starting, escalating to 3.0 mg (Saxenda) or 1.2-1.8 mg (Victoza)
Frequency
Once daily
Duration
Ongoing (chronic therapy)
Step-wise Titration (5 weeks)
Administration
Route
SCSchedule
Once daily
Timing
Any time of day, without regard to meals; same time each day recommended
โ Rotate injection sites
Cycle
Duration
Ongoing (chronic therapy)
Repeatable
Yes
Preparation & Storage
โ Ready-to-use โ no reconstitution required
Storage: Store refrigerated at 2-8 degrees C (36-46 degrees F). Do not freeze. After first use, pen may be stored at room temperature (up to 30 degrees C / 86 degrees F) or refrigerated for up to 30 days.
โ๏ธ Suggested Bloodwork (6 tests)
HbA1c and fasting glucose
When: Baseline
Why: Baseline glycemic control
Lipid panel
When: Baseline
Why: Baseline cardiovascular markers
CMP with liver enzymes
When: Baseline
Why: Liver and kidney function
Thyroid panel (TSH, free T4)
When: Baseline
Why: Rule out thyroid disorders (black box MTC warning)
Amylase and lipase
When: Baseline
Why: Baseline pancreatic function
HbA1c
When: 12 weeks
Why: Monitor glycemic improvement
๐ก Key Considerations
- โContraindication: Avoid with personal/family history of medullary thyroid carcinoma or MEN2 syndrome; contraindicated in pregnancy
- โSaxenda: Discontinue if less than 4% weight loss after 16 weeks at 3.0 mg
- โDo not use with other GLP-1 receptor agonists or with insulin for Saxenda
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Type 2 Diabetes (Victoza) | Start 0.6 mg daily SC for 1 week, then increase to 1.2 mg daily. May increase to 1.8 mg daily after at least 1 week at 1.2 mg if additional glycemic control needed. | Once daily subcutaneous injection | Ongoing; long-term maintenance therapy | 0.6 mg is the starting dose for GI tolerability, not a therapeutic dose. The 1.2 mg dose provides clinically meaningful glycemic control for most patients. The 1.8 mg dose provides additional HbA1c reduction. |
| Weight Management (Saxenda) | Start 0.6 mg daily SC for 1 week, then escalate weekly: 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4), 3.0 mg (week 5 onward). | Once daily subcutaneous injection | Ongoing; long-term weight management | Target maintenance dose is 3.0 mg daily. If patient does not tolerate dose increase, delay escalation by 1 week. Discontinue if patient has not lost at least 4% of body weight after 16 weeks at the 3.0 mg dose. |
| Adolescent Obesity (Saxenda, ages 12-17) | Start 0.6 mg daily SC for 1 week, then escalate weekly by 0.6 mg increments to 3.0 mg daily or maximum tolerated dose. | Once daily subcutaneous injection | Ongoing with periodic reassessment | Same escalation as adult Saxenda protocol. Approved for adolescents aged 12-17 years with body weight above 60 kg and BMI corresponding to 30 kg/m2 or greater for adults. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Liraglutide (Victoza/Saxenda) is supplied as a pre-filled, multi-dose pen device. No reconstitution, mixing, or dilution is required. Victoza pens contain 18 mg/3 mL (6 mg/mL). Saxenda pens contain 18 mg/3 mL (6 mg/mL). Each pen includes disposable pen needles that are attached before each injection.
Recommended Injection Sites
- โAbdomen (at least 2 inches from navel)
- โFront of thigh (middle third)
- โUpper arm (back, upper outer area -- may require assistance)
๐งStorage Requirements
Store refrigerated at 2-8 degrees C (36-46 degrees F). Do not freeze. After first use, pen may be stored at room temperature (up to 30 degrees C / 86 degrees F) or refrigerated for up to 30 days. Protect from direct heat and sunlight. Keep pen cap on when not in use. Discard pen after 30 days even if medication remains.
Community Dosing Protocols
Compare these clinical doses with what 200+ community members report using.
Based on 200+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Prescribing Information#
Liraglutide is an FDA-approved prescription medication marketed as Victoza (type 2 diabetes) and Saxenda (weight management). All dosing information below is based on FDA-approved prescribing information and clinical trial protocols. Liraglutide must be prescribed and supervised by a qualified healthcare provider.
Dose Escalation: Victoza (Type 2 Diabetes)#
Starting Dose#
All patients begin with 0.6 mg administered once daily by subcutaneous injection for at least 1 week. The 0.6 mg dose is not intended as a therapeutic dose for glycemic control; it serves as a tolerability-building dose.
Escalation Steps#
| Week | Dose | Status |
|---|---|---|
| 1 | 0.6 mg daily | Starting (non-therapeutic) dose |
| 2+ | 1.2 mg daily | First therapeutic dose |
| 3+ | 1.8 mg daily | Maximum dose (if additional control needed) |
The 1.2 mg dose is the recommended therapeutic dose for most patients. The 1.8 mg dose provides incremental HbA1c reduction for patients needing additional glycemic control.
Clinical Outcomes by Dose (LEAD Trials)#
- 1.2 mg daily: HbA1c reduction of approximately 1.0-1.2%
- 1.8 mg daily: HbA1c reduction of approximately 1.1-1.5%
Dose Escalation: Saxenda (Weight Management)#
Escalation Schedule#
Saxenda uses a 4-week escalation to the 3.0 mg maintenance dose:
| Week | Dose | Status |
|---|---|---|
| 1 | 0.6 mg daily | Initiation dose |
| 2 | 1.2 mg daily | Escalation dose |
| 3 | 1.8 mg daily | Escalation dose |
| 4 | 2.4 mg daily | Escalation dose |
| 5+ | 3.0 mg daily | Maintenance dose |
The maintenance dose of 3.0 mg daily is the target for weight management. This dose was used in the SCALE clinical trials. If a patient cannot tolerate dose escalation, the increase may be delayed by an additional week.
Treatment Response Assessment#
The FDA label includes a stopping rule: discontinue Saxenda if the patient has not achieved at least 4% weight loss after 16 weeks at the 3.0 mg dose, as it is unlikely to achieve clinically meaningful weight loss with continued treatment.
Clinical Outcomes (SCALE Trials)#
- SCALE Obesity: 3.0 mg daily achieved 8.0% mean weight loss at 56 weeks (vs 2.6% placebo)
- SCALE Diabetes: 3.0 mg daily achieved 6.0% mean weight loss in patients with T2D
- SCALE Maintenance: 3.0 mg daily maintained and extended weight loss after initial low-calorie diet
- SCALE Teens: 3.0 mg daily achieved significant BMI reduction in adolescents aged 12-17
Administration Technique#
Pre-Filled Pen Devices#
Victoza: Multi-dose pen containing 18 mg/3 mL liraglutide. Each pen delivers doses of 0.6 mg, 1.2 mg, or 1.8 mg and provides multiple daily doses.
Saxenda: Multi-dose pen containing 18 mg/3 mL liraglutide. Each pen delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg. Each pen provides approximately 5-6 doses at the 3.0 mg maintenance dose.
Injection Procedure#
-
Preparation: Remove pen from refrigeration and allow to reach room temperature (approximately 30 minutes if stored in refrigerator). Attach a new pen needle. Inspect the solution: it should be clear and colorless. Do not use if cloudy, discolored, or containing particles.
-
Site selection: Choose an injection site on the abdomen (at least 2 inches from the navel), front of the thigh, or back of the upper arm. Rotate sites with each injection.
-
Injection: Insert the needle into the skin, press the dose button, and hold for 6 seconds to ensure complete delivery.
-
Disposal: Remove and dispose of needle in a sharps container after each injection. Replace pen cap.
Timing and Missed Doses#
- Dosing time: Administer at any time of day, without regard to meals. The same time each day is recommended for convenience and adherence.
- Missed dose: If missed, take the next dose at the scheduled time. Do not take an extra dose or increase the dose to make up for a missed dose.
- Changing dosing time: The time of day may be changed without dose adjustment.
Storage Requirements#
Before First Use#
- Refrigerate at 2-8 degrees C (36-46 degrees F)
- Do not freeze. Discard if frozen.
- Store in original carton to protect from light
After First Use#
- Store at room temperature (up to 30 degrees C / 86 degrees F) or refrigerated for up to 30 days
- Keep pen cap on when not in use
- Discard pen 30 days after first use, even if medication remains
- Do not store with needle attached
Special Dosing Considerations#
Renal Impairment#
No dose adjustment is recommended. However, experience in severe renal impairment (eGFR <15 mL/min/1.73m2) is limited. Caution advised due to potential dehydration from GI adverse events.
Hepatic Impairment#
No dose adjustment required based on pharmacokinetic studies. Use with caution in patients with hepatic impairment.
Elderly Patients#
No dose adjustment required based on age. Clinical trials included patients over 65 with comparable safety profiles.
Concomitant Insulin or Sulfonylurea#
When adding liraglutide to insulin or sulfonylurea therapy, consider reducing the dose of the concomitant medication to reduce hypoglycemia risk.
Switching to/from Other GLP-1 Agonists#
Do not use liraglutide concomitantly with other GLP-1 receptor agonists. When switching from liraglutide to semaglutide, begin the new agent on the day after the last liraglutide dose, starting with the recommended initiation dose.
Clinical Dosing Outcomes Summary#
| Indication | Brand | Dose | Key Outcome | Trial |
|---|---|---|---|---|
| T2D | Victoza | 1.2 mg | HbA1c -1.0 to -1.2% | LEAD |
| T2D | Victoza | 1.8 mg | HbA1c -1.1 to -1.5% | LEAD |
| T2D (CV) | Victoza | 1.8 mg | MACE -13% | LEADER |
| Obesity | Saxenda | 3.0 mg | Weight -8.0% | SCALE Obesity |
| Obesity + T2D | Saxenda | 3.0 mg | Weight -6.0% | SCALE Diabetes |
| Adolescent | Saxenda | 3.0 mg | Significant BMI reduction | SCALE Teens |
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Liraglutide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.